PPI Test in GP Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00318084|
Recruitment Status : Completed
First Posted : April 26, 2006
Last Update Posted : August 17, 2007
|Condition or disease||Intervention/treatment||Phase|
|GERD||Drug: Esomeprazole Procedure: Ambulatory 24-hour esophageal pH-monitoring||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Proton Pump Inhibitor Test in Reflux Disease: a Study Using Nexium in General Practice Patients|
|Study Start Date :||January 2003|
- Diagnostic test characteristics and the positive and negative predictive value of a 2-week Nexium-based PPI test using symptom analysis of 24-hour esophageal pH monitoring as gold standard.
- To assess the optimal duration of a Nexium-based PPI test, and the predictive value of different symptoms for presence of reflux-related symptoms.
- Obtain information on patient satisfaction, the course of reflux symptoms, the consumption of acid suppressing drugs, the disease-related quality of life at a follow up periods of 3 months in patients with a positive and negative PPI test.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00318084
|Study Director:||AstraZeneca Netherlands Medical Director||AstraZeneca|